Thermo-Responsive Hydrogel Microcapsule Ocular Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery systems for treating conditions like choroidal neovascularization secondary to age-related macular degeneration, such as anti-VEGF therapeutics, require frequent intravitreal injections, which can lead to complications and have low patient compliance, especially after ocular surgery, due to the need for repeated administration of topical antibiotics.
Innovation Solution
A hydrogel delivery composition comprising degradable microcapsules suspended in a thermo-responsive hydrogel that changes from a liquid-like state at room temperature to a solid state at body temperature, allowing controlled release of treatment agents like anti-VEGF, reducing the frequency of injections and improving patient compliance by providing extended and localized drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If degradable microcapsules are injected into the eye as independent units to control drug release, then the duration of action is improved, but the reliability deteriorates because they can become lodged in ocular tissues causing unintended complications
Solution Approach 1:
The patent combines degradable microcapsules with a thermo-responsive hydrogel into a single integrated delivery system. The microcapsules are suspended within the hydrogel matrix, which provides structural support and guides the microcapsules to the intended delivery site (vitreous humor) while preventing them from becoming lodged in ocular tissues. This merging resolves the contradiction by maintaining the extended drug release capability of microcapsules while eliminating their harmful lodging effect through the hydrogel's stabilizing and directing function.
Solution Approach 2:
The thermo-responsive hydrogel acts as an intermediary between the microcapsules and the ocular environment. It mediates the delivery process by providing a controlled matrix that holds the microcapsules, enables safe injection through needle delivery, and ensures proper distribution in the target tissue. The hydrogel intermediate prevents direct harmful interaction between free microcapsules and ocular structures while still allowing controlled drug release.
2Reliability
If frequent intravitreal injections are administered to deliver anti-VEGF therapeutics, then the effectiveness of treatment is improved, but the object-affected harmful factors worsen due to complications such as endophthalmitis, retinal detachment, and cataract
Solution Approach 1:
The patent employs preliminary action by formulating a single-dose delivery system that releases the drug over an extended period (months). The hydrogel-microcapsule composition is designed to provide sustained anti-VEGF therapy, eliminating the need for repeated monthly injections. This preliminary comprehensive dosing achieves the same or better treatment effectiveness while avoiding the cumulative harmful effects of multiple injection procedures.
Solution Approach 2:
The delivery system provides continuous drug release over an extended period through the controlled degradation of the hydrogel matrix and microcapsules. This continuous action maintains therapeutic drug levels in the eye without requiring repeated injections, thereby achieving sustained treatment effectiveness while eliminating the periodic harmful interventions associated with frequent injections.
3Duration of action of moving object
If microcapsules are used to control and extend drug release, then the duration of action is improved, but the device complexity increases due to the need for suspension in hydrogel and controlled degradation mechanisms
Solution Approach 1:
The patent utilizes parameter changes, specifically the thermo-responsive phase transition of the hydrogel, to simplify the delivery system. The hydrogel transitions from a liquid-like state at room temperature (facilitating injection) to a solid state at body temperature (providing structural support and controlled release). This parameter change enables the system to achieve extended drug release without complex mechanical structures, as the physical state transition itself provides the necessary control mechanisms.
Solution Approach 2:
The thermo-responsive hydrogel undergoes a phase transition from liquid to gel upon injection into the eye, where it reaches physiological temperature. This phase transition simplifies the delivery system by providing automatic structural organization and drug release control without requiring complex external mechanisms. The phase change itself creates the controlled environment for extended drug release while maintaining ease of administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hydrogel delivery system achieves a controlled and extended release of bioactive drugs, reducing the initial burst effect, maintaining bioactivity over time, and potentially replacing monthly injections with a six-month treatment regimen, thereby minimizing complications and improving socio-economic impact.
Implementation Method 1
The hydrogel is thermo-responsive in that it desirably changes its physical state from a liquid-like state at room temperature to a more solid state at body temperature (e.g., at a physiological temperature of about 32° C. to about 37° C.)
Implementation Method 2
degradable microcapsules (e.g., nano- or micro-spheres or other similar microencapsulation structures) suspended in a degradable thermo-responsive hydrogel
Data Source
AI summary
A hydrogel delivery composition, including degradable microcapsules suspended in a degradable thermo-responsive hydrogel. The hydrogel is thermo-responsive at a physiological temperature and changes after application to a more solid state due to body temperatures. The composition includes one or more treatment agents to be released over time as the composition degrades. The composition can be varied to modify the structure and/or release of the treatment agent.